This document summarizes the contents of a 2008 report on the central nervous system drug pipeline. The report analyzed over 9,200 drug products across 1,230 biotech and pharmaceutical companies. It provides breakdowns of the pipeline by therapeutic area and development stage, as well as descriptions of individual drug candidates and licensing deals in the CNS sector. The document promotes the report's in-depth analysis of the CNS drug landscape and profiles of key decision makers within companies.

1. 13 KEY THERAPEUTIC AREAS WITH OVER 55,000 PRODUCT ANALYZED & Extract from our 2008 CNS pipeline report Pipeline Analysis Portfolio 2009 For your consideration

2. Available across 13 therapeutic areas! 4228 1028 Autoimmune & Inflammation new! 1464 462 Women’s Health 3347 829 Respiratory Care 3620 792 Dermatology 4334 853 Gastrointestinal 10845 1200 Infectious Disease 7043 1108 Cancer 9220 1230 CNS 6265 912 Cardiovascular 1965 9628 422 847 Ophthalmology new! Metabolic & Endocrinology (Diabetes) new! products Reviewed No. of pipelines Therapeutic Area

3. 2008 CNS Pipeline report Overview of 1230 companies in CNS area and breakdown of their pipeline by the developmental stage (from pre-clinical to market stage)

4. CNS pipeline product description of 9200 products from 1230 companies (pre-clinical to marketing status) (Company Name, Product, Description, Trial Details…

5. … and also…Phase, Indication, Diseasehubs, MOA, Drug Class information on over 9200 pipeline products reviewed…

6. CNS pipeline pivot table - Breakdown of 1230 companies pipelines by their indication areas and development stages (PC-Market) (covering from smallest biotechs to largest pharma companies)

7. PivotChart of companies pipeline development, broken down by the indication area (i.e. Wyeth CNS pipeline below)

8. Overview of ALL compounds across the 1230 companies analyzed breakdown by an indication area and a development stage (i.e. Multiple Sclerosis Phase II – 40 products)… and …

9. … those 40 products extracted, for quicker access, from a list of 9200 products

10. Overview of financial performance of 1230 companies analyzed

11. Overview of KEY LICENSING DEALS in CNS sector – intel on Component, Source, Partners …

12. … and also… Deal Type, Milestone in $mil, Deal Title and Deal Summary

13. CNS deals (mergers, acquisitions, license, commercialization, development, marketing…) – intel on all companies analyzed

14. New in 2009 ! Contact info on KEY DECISION MAKERS within the companies analyzed